In vitro susceptibility of sea lion poxvirus to cidofovir

Antiviral Research

Volumn 80, Issue 1, 2008, Pages 77-80

  Nollens, Hendrik H ^a   Gulland, Frances M D ^b   Jacobson, Elliott R ^a   Hernandez, Jorge A ^c   Klein, Paul A ^d   Walsh, Michael T ^a   Condit, Richard C ^e  

^a Scott)   (United States)

^b THE MARINE MAMMAL CENTER   (United States)

^c University of Florida College of Veterinary Medicine   (United States)

^d Department of Clinical and Health Psychology   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acyclovir; Cidofovir; Isatin beta thiosemicarbazone; Parapoxvirus; Phosphonoacetic acid; Poxvirus; Rifampicin; Sea lion; Seal; Treatment

Indexed keywords

ACICLOVIR; CIDOFOVIR; ISATIN 3 THIOSEMICARBAZONE; PHOSPHONOACETIC ACID; RIFAMPICIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; IN VITRO STUDY; MONOLAYER CULTURE; NONHUMAN; PARAPOXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; SEAL; VIRUS ISOLATION; VIRUS REPLICATION; ZALOPHUS CALIFORNIANUS;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; CYTOSINE; KIDNEY; MICROBIAL SENSITIVITY TESTS; PARAPOXVIRUS; PHOSPHONIC ACIDS; POXVIRIDAE INFECTIONS; SEA LIONS;

OTARIIDAE; PARAPOXVIRUS; PINNIPEDIA; POXVIRIDAE; ZALOPHUS CALIFORNIANUS;

EID: 50049099121     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.03.007     Document Type: Article

References (33)

1. American Society of Hospital Pharmacists, 2003. American hospital formulary service drug information.
2. Baldick Jr. C.J., and Moss B. Resistance of vaccinia virus to rifampicin conferred by a single nucleotide substitution near the predicted NH2 terminus of a gene encoding an Mr 62,000 polypeptide. Virology 156 (1987) 138-145
3. Becher P., König M., Müller G., Siebert U., and Thiel H.J. Characterization of sealpox virus, a separate member of the parapoxviruses. Arch. Virol. 147 (2002) 1133-1140
4. Buller R.M., Owens G., Schriewer J., Melman L., Beadle J.R., and Hostetler K.Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318 (2004) 474-481
5. Clark C., McIntyre P.G., Evans A., McInnes C.J., and Lewis-Jones S. Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic. Br. J. Dermatol. 152 (2005) 791-793
6. Condit R.C., Easterly R., Pacha R.F., Fathi Z., and Meis R.J. A vaccinia virus isatin-beta-thiosemicarbazone resistance mutation maps in the viral gene encoding the 132-kDa subunit of RNA polymerase. Virology 185 (1991) 857-861
7. Crumpacker C.S. Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 92 (1992) 3S-7S
8. Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36 (1999) 127-143
9. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23 (2002) 456-458
10. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55 (2002) 1-13
11. Degraeve C., De Coninck A., Senneseael J., and Roseeuw D. Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology 198 (1999) 162-163
12. Elion G.B. The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. 12 Suppl. B (1983) 9-17
13. Geerinck K., Lukito G., Snoeck R., De Vos R., De Clercq E., Vanrenterghem Y., Degreef H., and Maes B. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64 (1998) 543-549
14. Hicks B.D., and Worthy G.A. Sealpox in captive grey seals (Halichoerus grypus) and their handlers. J. Wildl. Dis. 23 (1987) 1-6
15. Magee W.C., Hostetler K.Y., and Evans D.H. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49 (2005) 3153-3162
16. McCabe D., Weston B., and Storch G. Treatment of orf poxvirus lesion with cidofovir cream. Pediatr. Infect. Dis. J. 22 (2003) 1027-1028
17. Mercer, A., Fleming, S., Robinson, A., Nettleton, P., Reid, H., 1997. Molecular genetic analyses of parapoxviruses pathogenic for humans. Arch. Virol. Suppl. 13, 25-34.
18. Morfin F., and Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26 (2003) 29-37
19. Murphy J.K., and Ralfs I.G. Bullous pemphigoid complicating human orf. Br. J. Dermatol. 134 (1996) 929-930
20. Nettleton P.F., Munro R., Pow I., Gilray J., Gray E.W., and Reid H.W. Isolation of a parapoxvirus from a grey seal (Halichoerus grypus). Vet. Rec. 137 (1995) 562-564
21. Nettleton P.F., Gilray J.A., Reid H.W., and Mercer A.A. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 48 (2000) 205-208
22. Nollens H.H., Gulland F.M.D., Jacobson E.R., Hernandez J.A., Klein P.A., Walsh M.T., and Condit R.C. Parapoxviruses of seals and sea lions make up a distinct subclade within the genus Parapoxvirus. Virology 349 (2006) 316-324
23. Nollens H.H., Jacobson E.R., Gulland F.M.D., Beusse D.O., Bossart G.D., Hernandez J.A., Klein P.A., and Condit R.C. Pathology and preliminary characterization of a parapoxvirus isolated from a California sea lion (Zalophus californianus). J. Wildl. Dis. 42 (2006) 23-32
24. Osterhaus A.D., Broeders H.W., Visser I.K., Teppema J.S., and Kuiken T. Isolation of a parapoxvirus from pox-like lesions in grey seals. Vet. Rec. 135 (1994) 601-602
25. Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., and Buller R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 77 (2008) 39-49
26. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., and Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48 (2004) 404-412
27. Reed L.J., and Muench H. A simple method for estimating fifty per cent endpoints. Am. J. Hyg. 27 (1938) 493-497
28. Reid H.W. Poxviruses. In: Palmer S.R., and Soulsby L.S.D.I.H. (Eds). Zoonoses. Biology, Clinical Practice and Public Health Control (1998), Oxford University Press, Oxford 415-421
29. Shelley W.B., and Shelley E.D. Surgical treatment of farmyard pox. Orf, milker's nodules, bovine papular stomatitis pox. Cutis 31 (1983) 191-192
30. Szajner P., Weisberg A.S., Lebowitz J., Heuser J., and Moss B. External scaffold of spherical immature poxvirus partciles is made of protein trimers, forming a honeycomb lattice. J. Cell Biol. 170 (2005) 971-981
31. Terry B.J., Mazina K.E., Tuomari A.V., Haffey M.L., Hagen M., Feldman A., Slusarchyk W.A., Young M.G., Zahler R., and Field A.K. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG. Antiviral Res. 10 (1988) 235-251
32. Tsankov N., and Angelova I. Rifampin in dermatology. Clin. Dermatol. 21 (2003) 50-55
33. Yirrell D.L., Reid H.W., Norval M., Entrican G., and Miller H.R. Response of efferent lymph and popliteal lymph node to epidermal infection of sheep with orf virus. Vet. Immunol. Immunopathol. 28 (1991) 219-235